October 1, 2025BJU InternationalOpen Access

The role of PSMA PET/CT in staging patients with intermediate‐risk prostate cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Systematic review reveals low diagnostic accuracy of PSMA PET/CT in intermediate-risk prostate cancer, suggesting limited utility.

PSMA PET/CT showed a low yield in staging intermediate-risk prostate cancer, highlighting its limited diagnostic utility.
A pooled analysis found a PSMA PET/CT positivity rate of 9%, with overall sensitivity at 33% for nodal and metastatic spread.
The review included 16 studies, reporting positivity rates in intermediate-risk prostate cancer from 2.2% to 50%, indicating variability.
The findings suggest a need for robust prospective studies to inform clinical guidelines and improve decision-making in prostate cancer.

Bonaddio et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark